** Shares of biotech firm Creative Medical Technology Holdings CELZ.O rise 16.1% to $5.33 premarket

** Co says its mid-term follow-up data showed its stem cell therapy, called StemSpine, was successful in treating chronic lower back pain and reducing opioid dependency

** Says the study shows significant improvements in pain levels and functional mobility

** Says no serious adverse events were reported

** Over 90% of patients reported no opioid use for pain management three years post-procedure, co says

** CELZ rose ~9% in the last 12 months

(Reporting by Siddhi Mahatole)

((siddhiprabhanjan.mahatole@thomsonreuters.com))